Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Calabrò, Luana; Ceresoli, Giovanni Luca; D'Incecco, Armida; Scherpereel, Arnaud; Aerts, Joachim; di Maio, Roberto

doi:10.1016/j.cytogfr.2017.07.003

Calabrò, L. (Luana), Ceresoli, G.L. (Giovanni Luca), D'Incecco, A. (Armida), A. Scherpereel (Arnaud), J.G.J.V. Aerts (Joachim) and R. di Maio (Roberto)

2017-08-01

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Cytokine and Growth Factor Reviews , Volume 36 p. 25- 31

Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.

Additional Metadata
Keywords	CTLA-4, Immune-checkpoint, Immunotherapy, Mesothelioma, PD-1, PD-L1
Persistent URL	doi.org/10.1016/j.cytogfr.2017.07.003, hdl.handle.net/1765/108651
Journal	Cytokine and Growth Factor Reviews
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Calabrò, L. (Luana), Ceresoli, G.L. (Giovanni Luca), D'Incecco, A. (Armida), Scherpereel, A., Aerts, J., & di Maio, R. (2017). Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 36, 25–31. doi:10.1016/j.cytogfr.2017.07.003

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Publication

Publication

About

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Publication

Publication

Workflow

Workflow

Add Content